** Medical device maker Medtronic's MDT.N shares rise 1% to $90.86
** U.S. FDA has approves co's deep brain stimulation system $(DBS)$ for use in patients with Parkinson's disease
** DBS uses a surgically implanted device called neurostimulator to send electrical signals to specific parts of the brain that have been affected by the neurological disorder
** The system adjusts the therapy to each person's brain activity in real time
** The tech will be available to Parkinson's patients who have been previously implanted with a neurostimulator, as well as future DBS patients - co
** Patient programmings in the United States will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months - MDT
** MDT rose 4.7% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。